University of Maryland School of Medicine (UMSOM) Researchers have identified a target that may improve the response of CAR T-cell therapy, a treatment for patients with recurrent or difficult to treat blood cancers.

In a recent study published in Signal Transduction and Targeted Therapy, scientists found increased survival and tumor-fighting activity in lab and animal models when they blocked a specific protein in the modified cells.